Atypical antipsychotic - Simple English Wikipedia, the free encyclopedia

Atypical antipsychotics, also called second-generation antipsychotics (SGAs), are a group of medicines used to treat mental health problems. They help people with conditions like schizophrenia, bipolar disorder, and other psychiatric disorders.

Definition

[change | change source]

Atypical antipsychotics are newer medicines that treat psychosis and other mental health conditions. They work differently from older antipsychotics (called first-generation antipsychotics or FGAs) and often have fewer side effects.[1]

The first atypical antipsychotic, clozapine, was made in the 1960s. More atypical antipsychotics were created in the 1990s. They became popular because they helped with symptoms and had fewer movement-related side effects than older medicines.

How Atypical Antipsychotics Work

[change | change source]

These medicines are thought to work in the brain by:

Types of Atypical Antipsychotics

[change | change source]

Some common atypical antipsychotics are:

  • Aripiprazole (Abilify)
  • Quetiapine (Seroquel)
  • Risperidone (Risperdal)
  • Brexpiprazole (Rexulti)
  • Cariprazine (Vraylar)
  • Clozapine (Clozaril)
  • Lurasidone (Latuda)
  • Olanzapine (Zyprexa)
  • Paliperidone (Invega)
  • Ziprasidone (Geodon)

Doctors use atypical antipsychotics to treat:

How They Are Given

[change | change source]

Atypical antipsychotics come in different forms:

Patients usually take them every day, but some are given as injections that last weeks or months.

Side Effects

[change | change source]

Like all medicines, atypical antipsychotics can cause side effects:

  • Weight gain and metabolic changes (like diabetes and high cholesterol)
  • Feeling sleepy or dizzy
  • Dry mouth or constipation
  • Blurred vision
  • Faster heartbeat
  • Changes in how the body moves (called extrapyramidal symptoms)
  • Increased prolactin levels (a hormone)

References

[change | change source]
  1. Meltzer, H. "What's atypical about atypical antipsychotic drugs?". Current Opinion in Pharmacology. 4 (1): 53–57. doi:10.1016/j.coph.2003.09.010.
  2. Seeman, Philip. "Atypical Antipsychotics: Mechanism of Action". The Canadian Journal of Psychiatry (in French). 47 (1): 27–38. doi:10.1177/070674370204700106. ISSN 0706-7437.
  3. Worrel, Jodi A.; Marken, Patricia A.; Beckman, Stephanie E.; Ruehter, Valerie L. (2000-02-01). "Atypical antipsychotic agents: A critical review". American Journal of Health-System Pharmacy. 57 (3): 238–255. doi:10.1093/ajhp/57.3.238. ISSN 1079-2082.